Patents by Inventor Peter Hammerman

Peter Hammerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms
    Patent number: 11926874
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: March 12, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Matthew Meyerson, Chandra Pedamallu, Sam Freeman
  • Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
    Patent number: 11624093
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 11, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Kwok-Kin Wong, Chunxiao Xu, Christine F. Brainson, Carla F. Kim, Glenn Dranoff, Peter Hammerman
  • COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
    Publication number: 20200338074
    Abstract: The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 29, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Kwok-kin Wong, Nathanael S. Gray
  • Combination therapy of transcription inhibitors and kinase inhibitors
    Patent number: 10702527
    Abstract: The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Kwok-kin Wong, Nathanael S. Gray
  • COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER USING PD-L1 ISOFORMS
    Publication number: 20200095644
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L1 levels.
    Type: Application
    Filed: August 2, 2019
    Publication date: March 26, 2020
    Inventors: Peter Hammerman, Matthew Meyerson, Chandra Pedamallu, Sam Freeman
  • DDR2 Mutations in Squamous Cell Lung Cancer
    Publication number: 20200087734
    Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.
    Type: Application
    Filed: August 12, 2019
    Publication date: March 19, 2020
    Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos
  • DDR2 mutations in squamous cell lung cancer
    Patent number: 10385403
    Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 20, 2019
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos
  • COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
    Publication number: 20190015411
    Abstract: The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
    Type: Application
    Filed: June 10, 2016
    Publication date: January 17, 2019
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Kwok-kin Wong, Nathanael S. Gray
  • COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
    Publication number: 20180169097
    Abstract: The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter Hammerman, Kwok-kin Wong, Nathanael S. Gray
  • DDR2 Mutations in Squamous Cell Lung Cancer
    Publication number: 20170029903
    Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos
  • DDR2 mutations in squamous cell lung cancer
    Patent number: 9499856
    Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: November 22, 2016
    Assignees: The Board Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos
  • Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms
    Publication number: 20160122829
    Abstract: The present invention relates to methods for identifying, assessing, preventing, and treating cancer (e.g., head, neck, and/or lung cancers in humans). A variety of PD-L1 isoforni biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with cancer status and indicates amenability to treatment or prevention by modulating PD-1 and/or PD-L! levels.
    Type: Application
    Filed: June 2, 2014
    Publication date: May 5, 2016
    Inventor: Peter Hammerman
  • DDR2 Mutations in Squamous Cell Lung Cancer
    Publication number: 20130261017
    Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.
    Type: Application
    Filed: May 1, 2013
    Publication date: October 3, 2013
    Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos